Conceptus, Inc. (Nasdaq: CPTS) $25.90. Announced Today that Conceptus has signed a definitive merger agreement with Bayer HealthCare LLC, Leverkusen, Germany.
With this acquisition, Bayer will be able to offer a complete range of short-term, long-term and permanent contraceptive choices for women. Within the next ten business days, Bayer will launch a public tender offer to acquire all shares of common stock of Conceptus, Inc. The transaction values Conceptus, Inc. at approx. US$1.1 billion (approx. EURO852 million) representing US$31.00 per share in cash. Closing is subject to customary conditions, in particular anti-trust approval in the U.S., and is expected by mid-year 2013.
What They Do: Conceptus, Inc. is the global leader in the development and commercialization of innovative device-based solutions in permanent birth control.
Broadwind Energy (Nasdaq: BWEN) $4.16. Today announced a $34 million order for towers from a U.S. wind turbine manufacturer. Broadwind will produce these towers in its Abilene, Texas facility with delivery scheduled to begin in fourth-quarter 2013 and extend into 2014.
“This order starts to fill the capacity in our Abilene facility into 2014,” said Peter Duprey, Broadwind Energy’s president and CEO. “This provides our tower business with better visibility further into the future. We continue to be pleased with the demand for domestically produced wind towers in the United States.”
What They Do: Broadwind Energy applies decades of deep industrial expertise to innovate integrated solutions for customers in the energy and infrastructure markets.
FX Energy (Nasdaq: FXEN) $3.44. Today announced results of a drill stem test (DST) on the Tuchola-3K well in north-central Poland. Gas flowed at a rate of approximately 5 million cubic feet per day with traces of condensate from a dolomite section in the Ca1/Upper Devonian. The Company now will run a 7" liner to a depth of approximately 2,700 meters and conduct a full production test over the next several days to determine whether to complete the well as a commercial discovery.
"We have not yet determined if the well is commercial," noted David Pierce, CEO, "but we are cautiously optimistic and therefore will run a liner to allow more thorough testing. We are also reviewing a range of possible follow-on actions, including other potential drilling locations, to appraise the scope and potential of this Ca1/Upper Devonian zone both nearby and right across our Edge concessions. We will have plans ready for a prompt response if the production test is encouraging."
FX Energy is the operator and owns 100% of the working interest in the Tuchola well and the four Edge concession blocks, which cover 880,000 acres or 3,567 square kilometers.
What They Do: FX Energy is an independent oil and gas exploration and production company with production in the US and Poland.
Protalix BioTherapeutics (NYSE: PLX) $5.51. Today announced that the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) and the Public Health Institute of Chile have both granted regulatory approval to UPLYSO(TM) (alfataliglicerase) for the long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease. UPLYSO will be marketed in Mexico and Chile by Pfizer Inc., the Company's commercialization partner.
UPLYSO is known as ELELYSO(TM) (taliglucerase alfa) outside of Latin America. Taliglucerase alfa was approved by the U.S. Food and Drug Administration in May 2012 and subsequently has been approved by Israel's Ministry of Health, Brazil's ANVISA and by the regulatory authorities of other countries.
What They Do: Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter.